Synthesis and NK1/NK2 binding activities of a series of diacyl-substituted 2-arylpiperazines

被引:10
作者
Blythin, DJ
Chen, X
Piwinski, JJ
Shih, NY
Shue, HJ
Anthes, JC
McPhail, AT
机构
[1] Schering Plough Corp, Res Inst, Dept Chem Res, Kenilworth, NJ 07033 USA
[2] Schering Plough Corp, Res Inst, Dept Allergy & Immunol, Kenilworth, NJ 07033 USA
[3] Duke Univ, Paul M Gross Chem Lab, Durham, NC 27708 USA
关键词
D O I
10.1016/S0960-894X(02)00645-5
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and binding affinity for hNK(1) and hNK(2) receptors of a series of diacyl substituted 2-aryl piperazines are described. SAR evaluation led to the racemic derivative 11g as an apparent dual inhibitor. Chiral chromatographic separation of 11g led to the observation that NK1 activity was shown by one enantiomer (13a) and NK2 activity was shown by the other enantiomer (13b). X-ray crystallographic analysis of the crystalline di-BOC derivative of the NK2, active piperazine (15) showed that the 2R configuration was associated with NK2 activity. Further derivatization indicated that dual NK1/NK2 activity could be built into the 2R series. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3161 / 3165
页数:5
相关论文
共 18 条
[1]   The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough [J].
Advenier, C ;
Lagente, V ;
Boichot, E .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (08) :1892-1906
[2]  
*AM CHEM SOC, 2001, 221 NAT M AM CHEM SO
[3]   Discovery of novel, orally active dual NK1/NK2 antagonists [J].
Bernstein, PR ;
Aharony, D ;
Albert, JS ;
Andisik, D ;
Barthlow, HG ;
Bialecki, R ;
Davenport, T ;
Dedinas, RF ;
Dembofsky, BT ;
Koether, G ;
Kosmider, BJ ;
Kirkland, K ;
Ohnmacht, CJ ;
Potts, W ;
Rumsey, WL ;
Shen, LH ;
Shenvi, A ;
Sherwood, S ;
Stollman, D ;
Russell, K .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (20) :2769-2773
[4]  
Chapman RW, 1998, DRUG NEWS PERSPECT, V11, P480
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   DISCOVERY OF A POTENT SUBSTANCE-P ANTAGONIST - RECOGNITION OF THE KEY MOLECULAR DETERMINANT [J].
DESAI, MC ;
LEFKOWITZ, SL ;
THADEIO, PF ;
LONGO, KP ;
SNIDER, RM .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (26) :4911-4913
[7]  
ELLIS JL, 1993, J PHARMACOL EXP THER, V267, P95
[8]  
FURCHGOTT RF, 1955, PHARMACOL REV, V7, P183
[9]  
Gerspacher Marc, 1999, Drugs of the Future, V24, P883, DOI 10.1358/dof.1999.024.08.858627
[10]  
GODEK DM, Patent No. 9118878